At the symposium, the team of Shenzhen Cell Valley and Fosun Kate respectively introduced the company's development, research and development and production pipeline, core technical advantages and other aspects in detail. Dr. Shi Yuanyuan, Chairman of the Board, said that the Shenzhen Cell Valley team has maintained close communication with the Fosun Kate team for a long time, and the two sides fully recognized the common points of industrial cooperation between them, and also saw the advantages and potential of their respective teams. As the only CRO/CDMO service platform with clinical grade retroviral vector GMP industrial production in China, Shenzhen Cell Valley hopes to further deepen cooperation with Fosun Kat team, promote complementary advantages, and achieve win-win development. Dr. Hao Shen, Chief Scientific Officer, made an in-depth analysis of the current international use trend of retroviral vectors and the use of domestic retroviral vectors, and expressed his hope to conduct in-depth cooperation with Shenzhen Cell Valley, make good use of the advantages of retroviral vectors in cost, production capacity and high transfection rate of some cell therapy products, and strongly combine with Shenzhen Cell Valley. Form benign communication with industry authorities to jointly promote the rationalization, scientific and standardized construction of the domestic CAR-T industry and the innovative research and development and promotion of cell therapy products based on retroviral vector technology.

Finally, the two sides around the new pipeline research and development, IIT, IND declaration, talent joint training, reduce CAR T production costs and other aspects of the cooperation model were deeply discussed, the two sides said that they will make good use of their own advantages, sincere cooperation, and jointly promote the whole industry chain of cell therapy high-quality rapid development.